By the immunostaining of GBM patient samples, patient-derived xenografts, and murine genetic subtype models, we show that TSPO expression is detected in tumor cells, as well as the tumor microenvironment, especially tumor-associated myeloid cells, pericytes, and endothelial cells, while LAT1 seems to be restricted to the tumor cells themselves. This evidence concerns the gene SLC7A5 and glioblastoma.